BR112022022578A2 - Novas composições e métodos de tratar doença covid-19 - Google Patents
Novas composições e métodos de tratar doença covid-19Info
- Publication number
- BR112022022578A2 BR112022022578A2 BR112022022578A BR112022022578A BR112022022578A2 BR 112022022578 A2 BR112022022578 A2 BR 112022022578A2 BR 112022022578 A BR112022022578 A BR 112022022578A BR 112022022578 A BR112022022578 A BR 112022022578A BR 112022022578 A2 BR112022022578 A2 BR 112022022578A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- methods
- new compositions
- covid
- treat covid
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 abstract 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 239000002559 chemokine receptor antagonist Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20173595.8A EP3906922A1 (en) | 2020-05-07 | 2020-05-07 | New compositions and methods of treating covid-19 disease |
| PCT/EP2021/061919 WO2021224356A1 (en) | 2020-05-07 | 2021-05-05 | New compositions and methods of treating covid-19 disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022578A2 true BR112022022578A2 (pt) | 2023-01-17 |
Family
ID=70617050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022578A BR112022022578A2 (pt) | 2020-05-07 | 2021-05-05 | Novas composições e métodos de tratar doença covid-19 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230157994A1 (https=) |
| EP (2) | EP3906922A1 (https=) |
| JP (1) | JP2023539542A (https=) |
| KR (1) | KR20240073720A (https=) |
| CN (1) | CN116133657A (https=) |
| AU (1) | AU2021269090A1 (https=) |
| BR (1) | BR112022022578A2 (https=) |
| CA (1) | CA3177779A1 (https=) |
| WO (1) | WO2021224356A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023517616A (ja) * | 2020-03-11 | 2023-04-26 | バイオラインアールエックス・リミテッド | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 |
| JP2023524522A (ja) * | 2020-05-01 | 2023-06-12 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤 |
| WO2022197625A1 (en) * | 2021-03-15 | 2022-09-22 | Drugarray, Inc. | Combination therapy for treating covid-19 |
| WO2022197627A1 (en) * | 2021-03-15 | 2022-09-22 | Drugarray, Inc. | Combination therapy for treating covid-19 |
| WO2022197626A1 (en) * | 2021-03-15 | 2022-09-22 | Drugarray, Inc. | Combination therapy for treating covid-19 |
| EP4085910A1 (en) * | 2021-05-05 | 2022-11-09 | 4Living Biotech | Use of a compound such as plerixafor for treating a viral pulmonary disease |
| CN114099531A (zh) * | 2021-12-16 | 2022-03-01 | 中国人民解放军军事科学院军事医学研究院 | 一种药物在治疗新型冠状病毒肺炎中的应用 |
| WO2024092069A1 (en) * | 2022-10-26 | 2024-05-02 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors for treatment of neurological diseases |
| CN121039852A (zh) | 2023-06-07 | 2025-11-28 | 株式会社Lg新能源 | 锂金属电池及包含该锂金属电池的电池模组和电池包 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892563B2 (en) * | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| TW200811138A (en) * | 2006-06-12 | 2008-03-01 | Pfizer Prod Inc | Pharmaceuticals |
| US20120064107A1 (en) * | 2010-05-18 | 2012-03-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other disease |
| CN110982945B (zh) * | 2020-03-04 | 2020-06-09 | 珠海丽珠试剂股份有限公司 | 一种检测2019新型冠状病毒的核酸组合物、试剂盒以及方法 |
-
2020
- 2020-05-07 EP EP20173595.8A patent/EP3906922A1/en not_active Withdrawn
-
2021
- 2021-05-05 AU AU2021269090A patent/AU2021269090A1/en not_active Abandoned
- 2021-05-05 EP EP21722910.3A patent/EP4146195A1/en not_active Withdrawn
- 2021-05-05 JP JP2022567359A patent/JP2023539542A/ja active Pending
- 2021-05-05 CA CA3177779A patent/CA3177779A1/en active Pending
- 2021-05-05 KR KR1020227041380A patent/KR20240073720A/ko active Pending
- 2021-05-05 CN CN202180033555.4A patent/CN116133657A/zh active Pending
- 2021-05-05 US US17/922,865 patent/US20230157994A1/en active Pending
- 2021-05-05 BR BR112022022578A patent/BR112022022578A2/pt not_active Application Discontinuation
- 2021-05-05 WO PCT/EP2021/061919 patent/WO2021224356A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4146195A1 (en) | 2023-03-15 |
| JP2023539542A (ja) | 2023-09-15 |
| CA3177779A1 (en) | 2021-11-11 |
| CN116133657A (zh) | 2023-05-16 |
| AU2021269090A1 (en) | 2022-12-01 |
| KR20240073720A (ko) | 2024-05-27 |
| EP3906922A1 (en) | 2021-11-10 |
| WO2021224356A1 (en) | 2021-11-11 |
| US20230157994A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR112021012654A2 (pt) | Métodos de tratamento de infecções por tempestade de citocina, incluindo covid-19, através da inibição da interação ccr5/ccl5 (rantes) e composições para a prática da mesma | |
| BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| BR112023016682A2 (pt) | Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista | |
| BR112022025946A2 (pt) | Composto, composição farmacêutica e método de tratamento de uma doença | |
| BR112022018948A2 (pt) | Métodos de tratamento de lesão pulmonar com inibidores de cgrp | |
| BR112023002085A2 (pt) | Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 | |
| BR112022001699A2 (pt) | Métodos e composições para reduzir imunogenicidade através de inibidores não deplecionais de célula b | |
| BR112023025738A2 (pt) | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção | |
| BR112022014925A8 (pt) | Inibidores macrocíclicos de rip2-quinase | |
| BR112023026992A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer | |
| BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
| BR112023014247A2 (pt) | Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas | |
| BR112022019338A2 (pt) | Tratamento preventivo de enxaqueca | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| BR112022003686A2 (pt) | Tratamento de sintomas induzidos pelo ciclo menstrual | |
| BR112022015869A2 (pt) | Composto, composição farmacêutica, métodos para inibir a ceto-hexoquinase e de tratamento e/ou prevenção de uma doença ou distúrbio, e, uso de um composto | |
| MX2022011651A (es) | Composicion farmaceutica para tratamiento de diabetes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |